Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,071 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Memorial Sloan Kettering Cancer Center Clear all
Completed Phase 1Phase 2 Interventional Results available

High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer

NCT00052429
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 15, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors

NCT04671901
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Childhood, Solid Carcinoma
Interventions
Romiplostim
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 15, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

NCT03615105
View directory record Official record
Conditions
Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide, Busulfan, Fludarabine, Melphalan, Clofarabine, HPC(A) stem cell allograft, Rituximab, Rabbit antithymocyte globulin
Radiation · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer

NCT00093405
View directory record Official record
Conditions
Kidney Cancer
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

NCT00052572
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
New York, New York • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 15, 2026, 2:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance

NCT00581646
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Leukemia, Non-Hodgkin's Lymphoma, Uterine Cancer, Vaginal Cancer, Infertility
Interventions
survey instrument
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 15, 2026, 2:07 AM EDT
Recruiting Early Phase 1 Interventional

A Study of Treatment Delivery Preference In People With Kidney Cancer

NCT07872553
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection, Pembrolizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma

NCT00586846
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cisplatin, Doxorubicin, Methotrexate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 15, 2026, 2:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors

NCT07030686
View directory record Official record
Conditions
Survivorship, Recurrent, Recurrence, Cancer, Remission
Interventions
Exercise
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02136797
View directory record Official record
Conditions
CMV Infection, Persistent CMV Viremia
Interventions
CMVpp65 Specific T-cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

NCT01690988
View directory record Official record
Conditions
Delirium
Interventions
Ketamine (0.5 mg/kg), Normal Saline (placebo), Ketamine (1 mg/kg)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 15, 2026, 2:07 AM EDT
Recruiting Phase 1 Interventional

The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

NCT04167969
View directory record Official record
Conditions
Prostate Cancer
Interventions
(64Cu)-NOTA-PSMAi-PEG-Cy5.5-C' dot tracer, PET/MRI/fluorescence imaging, Blood and urine sampling, laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection, 89Zr-DFO-PSMAi-PEG-Cy5.5-C' dots
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 15, 2026, 2:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Safety Study Assessing the Effects of Receiving Genome Sequencing Results

NCT01692223
View directory record Official record
Conditions
History of Cancer
Interventions
qualitative interviews
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

NCT00705250
View directory record Official record
Conditions
Hodgkin's Disease, Lymphoma
Interventions
bendamustine hcl
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 15, 2026, 2:07 AM EDT
Active, not recruiting Not applicable Interventional

Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease

NCT05048459
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Standard surveillance, Telemedicine surveillance (tele-surveillance), Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00027560
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 15, 2026, 2:07 AM EDT
Recruiting Phase 2 Interventional

Tislelizumab in People With Colorectal Cancer

NCT06529523
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Tislelizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Comparing Distress Screening + Consultation With Enhanced Usual Care for Caregivers of Cancer Patients

NCT03856086
View directory record Official record
Conditions
Cancer Caregivers
Interventions
Baseline questionnaire, NCCN Problem List, FACT-GP, HADS, CSS-CG
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

NCT01248962
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 15, 2026, 2:07 AM EDT
Active, not recruiting Phase 2 Interventional

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

NCT04761770
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myelodysplastic/Myeloproliferative Overlapping Syndrome
Interventions
Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells
Other · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 15, 2026, 2:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

NCT03107416
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
Hepatic artery embolization (HAE), Bumetanide
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

NCT01970306
View directory record Official record
Conditions
Esophageal Adenocarcinoma
Interventions
MatriStem PSM
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Harrison, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors

NCT00594633
View directory record Official record
Conditions
Brain Tumor, Brain Cancer, Cns Cancer, Cognitive Dysfunction
Interventions
donepezil and questionaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 15, 2026, 2:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD

NCT02406651
View directory record Official record
Conditions
Acute Graft vs Host Disease
Interventions
Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Duarte, California • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 15, 2026, 2:07 AM EDT